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AbstrACt
Introduction Fatigue remains pervasive, disabling 
and challenging to manage across all inflammatory 
rheumatic diseases (IRDs). Non-pharmacological 
interventions, specifically cognitive-behavioural 
approaches (CBAs) and graded exercise programmes 
designed to support and increase exercise, are valuable 
treatments which help patients with IRD to manage 
their fatigue. Yet, healthcare systems have encountered 
substantial barriers to the implementation of these 
therapeutic options. Lessening the Impact of Fatigue in 
Inflammatory Rheumatic Diseases: a Randomised Trial 
(LIFT) is designed to give insights into the effectiveness 
of a remotely delivered standardised intervention for 
a range of patients with IRD. It will also enable the 
exploration of putative moderating factors which may 
allow for the future triage of patients and to investigate 
the precise mediators of treatment effect in IRD-related 
fatigue.
Methods and analysis LIFT is a pragmatic, multicentre, 
three-arm randomised, controlled trial, which will 
test whether adapted CBA and personalised exercise 
programme interventions can individually reduce the 
impact and severity of fatigue. This will be conducted 
with up to 375 eligible patients diagnosed with IRD and 
interventions will be delivered by rheumatology healthcare 
professionals, using the telephone or internet-based audio/
video calls.
Ethics approval and dissemination Ethical approval 
has been granted by Wales REC 7 (17/WA/0065). 
Results of this study will be disseminated through 
presentation at scientific conferences and in scientific 
journal. A lay summary of the results will be sent to 
participants.
trial registration number NCT03248518; Pre-results.
IntroduCtIon 
Despite major advances in the management 
of inflammatory rheumatic diseases (IRDs), 
patients remain burdened by their disease and 
cite fatigue as a principal problem. In rheu-
matoid arthritis (RA), for example, as many 
as 80% of patients report significant fatigue1 
and over 70% consider fatigue to be equal to 
pain in terms of burden.2 Moreover, fatigue 
is a crucial determinant of impaired quality 
of life3 4 and a predictor of work disability.5 6 
strengths and limitations of this study
 ► Lessening the Impact of Fatigue in Inflammatory 
Rheumatic Diseases: a Randomised Trial is designed 
to give insights into the effectiveness of a remotely 
delivered standardised intervention for a range of 
patients with inflammatory rheumatic disease (IRD).
 ► It will also enable the exploration of putative moder-
ating factors which may allow for the future triage of 
patients and to investigate the precise mediators of 
treatment effect in IRD-related fatigue.
 ► Although participants and therapist are not blinded 
to treatment allocation, all research staff at study 
sites performing assessments are blinded.
 ► The availability of rheumatology healthcare profes-
sionals to be trained as therapists for the study may 
be restricted.
 ► Patients responding to study invitation may not rep-
resent the entire population, however, we seek to 
mitigate this by considering all patients, with a rele-
vant diagnosis, managed at each recruiting hospital.
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Indeed, over 75% of patients identify fatigue as the main 
barrier to remaining in employment.7 Studies in other 
chronic IRDs, such as axial spondyloarthritis (AxSpA) 
and systemic lupus erythematosus (SLE), have reported 
similar fatigue prevalence of 66%–85%8 9 and report the 
impact of fatigue on quality of life and employment to 
be equally pronounced.10–12 In spite of these profound 
consequences, patients feel that this symptom is clinically 
neglected13 14 and rheumatologists admit uncertainty 
regarding its management.15 
This situation reflects the poor availability of suitable inter-
ventions within traditional healthcare systems such as the 
National Health Service (NHS), but this is not to say that 
effective treatments do not exist. There is now a considerable 
consensus across the healthcare community that non-phar-
macological interventions, specifically cognitive-behavioural 
approaches (CBAs) and programmes designed to support 
increased exercise, are valuable treatments which help 
patients with IRD to manage the fatigue associated with their 
chronic diseases.16 17
Our current team has made key contributions to the 
evidence base, which supports the use of these treatments 
for fatigue in IRDs.18–20 However, current healthcare 
systems pose to substantial barriers to the implementa-
tion of these therapeutic options as part of standard clin-
ical care.
First, existing studies—including our own—have only 
developed bespoke disease-specific models of care, which 
vary in content, structure and method of delivery. Inev-
itably, this necessitates the development of multiple 
particular skill sets and duplicated pathways for the 
care providers if they are to equitably serve their diverse 
patient populations—a time consuming, costly and ineffi-
cient undertaking.
Second, patients find it challenging to commit to 
regular face-to-face treatment sessions (a common under-
pinning of existing CBA and exercise interventions). This 
is often due to a combination of health complications and 
the time-constrained nature of modern life, particularly 
relevant to those patients still in employment.
Third, individual patients report substantial variation 
in their preference and response to the distinct interven-
tions of CBA and exercise.21 22
rationale for study
It is becoming increasingly clear that:
a. Similarities exist across chronic IRDs regarding the na-
ture and likely mechanisms which maintain fatigue—
such as dysfunctional activity behaviours23–25 and illness 
beliefs14 26 27and so the application of standardised ge-
neric, rather than disease-specific, interventions may 
prove effective.
b. Alternative, more flexible, methods of remote deliv-
ery such as telephone and internet-based audio/video 
calls can be just as effective as traditional face-to-face 
interventions.28 29
c. In the future, the identification of baseline patient 
preferences and characteristics which can predict 
differential treatment effects (moderators) will be vital 
to inform a personalised triage approach to care.22 30
Therefore, a pragmatic study is proposed, which will 
use CBA and personalised exercise programme (PEP) 
interventions, informed by previously developed inter-
ventions31 32 which will be generically applicable across 
IRD-related fatigue populations. We will test whether 
these two key non-pharmacological interventions 
compared with usual care alone can individually reduce 
fatigue, when delivered by the rheumatology team, across 
a mixture of IRDs using telephone or internet-based 
audio/video calls. In doing so, this will enable us to 
explore potential moderating factors which may allow for 
the future triage of patients according to the most suitable 
intervention, as well as to investigate the precise media-
tors of the effect of treatment on IRD-related fatigue.
objectives
Primarily, we seek to test the hypothesis that either stan-
dardised CBA or PEP interventions, in addition to usual 
care, is more effective than usual care alone to lessen the 
impact and severity of fatigue. We will also explore the 
underlying moderators (in order to inform future patient 
triage) and mediators (in order to optimise future inter-
ventions) of IRD-related fatigue.
MEthods And AnAlysIs
study description
Lessening the Impact of Fatigue in Inflammatory Rheu-
matic Diseases: a Randomised Trial (LIFT) is a multi-
centre, three-arm randomised controlled trial testing 
usual care with additional adapted CBA or PEP interven-
tions versus usual care alone. Eligible participants will be 
identified from approximately 3600 patients with IRD 
attending major secondary care rheumatology services 
in the UK (figure 1). Recruitment for the study began 
in August 2017. We anticipate recruiting 375 participants 
previously diagnosed with IRD.
The timeline for assessment and delivery of inter-
ventions is summarised in figure 2. We anticipate that 
active CBA and PEP interventions will start between 2 
and 8 weeks post-randomisation, with an average delay 
of 4 weeks after randomisation. Follow-up data will be 
collected from all participants at 10 weeks, 28 weeks and 
56 weeks after randomisation adjusted for the average 
delay of 4 weeks, therefore all participants will remain 
part of the study for 13 months.
Participant recruitment and eligibility
Enrolment is by invitation only and all potential partic-
ipants will undergo a two-step screening process 
consisting of a prestudy invite and an assessment of their 
hospital medical notes. Patients with rheumatologist diag-
nosed IRDs (eg, RA, SLE and AxSpA, psoriatic arthritis, 
vasculitis or Sjögren’s syndrome) will receive a mailed 
prestudy invite consisting of a cover letter (see online 
supplementary file 1 for details on study within a trial), 
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study information and questions to explore interest and 
eligibility.
After return of the required prestudy screening ques-
tions, the research personnel at each site will assess their 
medical notes to determine eligibility based on the inclu-
sion and exclusion criteria (table 1).
A trained rheumatology research nurse will review and 
confirm eligibility. In addition, the local rheumatology 
consultant will have the opportunity to withdraw or 
exclude participants. If a participant has been identified 
as potentially eligible, she/he will be invited to an appoint-
ment for a baseline assessment visit at the local study site.
Figure 1 Study flow chart. Patients diagnosed with IRD will be invited by post and asked to return the prestudy screening 
questions. Screening is a two-step process using screening questions and review of medical records to establish fatigue state 
and identify other exclusion criteria. Potential participants will be contacted by phone to verify eligibility criteria and invited to 
the baseline assessment visit. After obtaining informed consent, their eligibility is confirmed (including fatigue states as well as 
determination of TSH, Hb and eGFR values if these were not available in the medical notes), baseline data are collected and 
participants are randomised into the study. At baseline, participants are also given a participant information sheet about the 
MRI substudy. Randomised participants will be contacted by the Trial Office in Aberdeen if they are also eligible to take part 
in the MRI substudy. CBA, cognitive-behavioural approach; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; IRD, 
inflammatory rheumatic disease; PEP, personalised exercise programme; TSH, thyroid stimulating hormone.
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Consenting participants
Patients will make a final decision to participate when they 
attend the local study site for the baseline assessment visit. 
No study-specific procedures will take place before written 
consent has been obtained. At the baseline assessment 
visit, a designated member of the local research team will 
confirm eligibility (including reconfirmation of fatigue 
state). It will also be determined whether the participant 
has ever met the relevant classification criteria for RA 
(mandatory, 2010 American College of Rheumatology 
Figure 2 Timeline intervention and assessment. CBA, cognitive-behavioural approach; PEP, personalised exercise programme. 
Table 1 Inclusion and exclusion criteria
In order to be considered eligible for participation in the study they must:
Criterion Characteristics of eligible participants
1. Be male or female aged ≥18 years at the time of consent.
2. Have been diagnosed with an IRD such as RA, SLE or AxSpA by a consultant rheumatologist.
3. Report fatigue to be a persistent problem as evidenced by answering both questions:
1. Have you had problems with fatigue for more than 3 months? (Yes).
2. Please circle the number that shows your average level of fatigue during the past 7 days. (≥6 based on a 
numerical rating scale of 0 (no fatigue) to 10 (totally exhausted)).
4. Have access to a telephone landline or mobile telephone and/or internet-based audio/video calls.
5. Give permission for researchers to access their hospital medical notes.
6. Have stable disease as evidenced by no change in immunomodulatory therapy within the last 3 months 
based on hospital medical records.
7. Currently be under the care of a secondary care physician.
Participants will be excluded if:
Criterion Characteristics of ineligible participants
1. There are significant abnormalities in thyroid function (TSH levels) in the most recent blood test done within 
the last 3 months.
2. There is evidence of severe anaemia (haemoglobin levels) in the most recent blood test done within the last 
3 months.
3. There is evidence of severe renal dysfunction (eGFR) in the most recent blood test done within the last 
3 months.
4. They have a medical condition which would make the proposed interventions unsuitable, for example, 
significant heart disease.
5. They are pregnant.
6. They are unable to understand English sufficiently to take part in the intervention.
7. They are unable to provide written informed consent.
8. They are not willing to be randomised.
9. They are currently participating in an interventional clinical trial.
AxSpA, axial spondyloarthritis; eGFR, estimated glomerular filtration rate; IRD, inflammatory rheumatic disease; RA, rheumatoid arthritis; SLE, 
systemic lupus erythematosus; TSH, thyroid stimulating hormone.
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(ACR)/European League Against Rheumatology 
(EULAR)33 or 1987 ACR34) or other IRDs (non-manda-
tory; SLE 1997 ACR SLE criteria,35 Assessment of Spon-
dyloArthritis international Society (ASAS criteria for 
AxSpA36).
randomisation
Participants will be allocated to receive either of the 
two treatments or usual care alone (1:1:1 ratio) using a 
computer-generated sequence. Randomisation will be 
minimised by diagnosis (RA, SLE, or AxSpA or other 
IRD) and the presence/absence of depressive symp-
toms (Hospital Anxiety and Depression Scale (HADS)37 
subscale score >10) and will include a random element 
set at 20%.
blinding
Full blinding will not be possible due to the need for 
participants to engage in specific behavioural change 
interventions. However, to reduce detection bias, we will 
aim to ‘blind’ research personnel undertaking outcome 
assessments to participants’ treatment allocation. To 
facilitate blinding, we will remind participants to refrain 
from discussing (and subsequently revealing) their treat-
ment allocation at follow-up assessments with research 
personnel. Finally, all data will be analysed blind to 
allocation.
Interventions and treatment protocol
Usual care
All participants will receive usual care and will receive 
a Versus Arthritis (formerly Arthritis Research UK) 
education booklet for self-management of fatigue38 by 
post. It represents usual care in almost all UK rheuma-
tology centres and is freely available. The booklet covers 
the major relevant topics (including fatigue validation, 
energy management, priorities, sleep, stress and asser-
tiveness) underpinned by goal setting and self-moni-
toring of activity. It encourages at several key points that 
the patient asks their rheumatology team for support to 
work through the booklet. We will not restrict what usual 
care may involve, but will monitor the care received for 
all participants as part of our health economics analysis.
Participants randomised to the active treatments will 
also receive either CBA or PEP. The CBA and PEP treat-
ments are adapted from previous fatigue-specific cogni-
tive behavioural31 32 and exercise interventions31 to ensure 
that they are suitable for a remote delivery via telephone 
or internet-based audio/video call and applicable to the 
broad spectrum of IRD.
Cognitive-behavioural approach
CBA is a structured psychological intervention, which 
explicitly aims to replace unhelpful beliefs and behaviours 
with more adaptive ones. In this study, the CBA will target 
a number of unhelpful behavioural patterns such as 
‘activity avoidance’ and ‘all or nothing’. These can lead 
to negative mood states, which exacerbates fatigue even 
further. Following a brief assessment of individual beliefs 
and behaviours surrounding fatigue, the aim of the treat-
ment is to change unhelpful beliefs and behavioural 
factors through the application of participant-centred 
strategies and behavioural activities, which are supported 
by written materials and regular consultations with rheu-
matology healthcare professionals. The participants will 
receive additional leaflets and diaries to assist them with 
making changes to manage fatigue.
Personalised exercise programme
PEP is based on the premise that chronic fatigue relates 
to exercise intolerance, supported by unhelpful illness 
beliefs (such as fear avoidance) and deconditioning, with 
a consequent increase of effort (perceived or otherwise). 
PEP aims to disrupt this vicious cycle by a graded expo-
sure behavioural therapy, which is symptom contingent, 
to gradually optimise patients’ levels of exercise with 
a view to modifying their altered perception of effort, 
improve their tolerance of exercise, fitness and func-
tion, reverse the deconditioning and ultimately reduce 
the severity and impact of fatigue. In this study, partic-
ipants will receive an individually tailored graded exer-
cise programme, delivered according to their physical 
capacity and gradually increased in duration and then 
intensity. The participants will receive additional informa-
tion and diaries to assist with the intervention. The inter-
vention will use pedometers and/or heart rate monitors 
to enhance motivation. Overall, the times and duration 
of exercise will be recorded in exercise diaries during the 
intervention.
Both CBA and PEP interventions will be delivered by 
healthcare professionals. PEP may be delivered by a rheu-
matology specialist physiotherapist and CBA may be deliv-
ered by a rheumatology nurse or an equally qualified and 
trained allied health professional (eg, occupational thera-
pist) who are members of local NHS staff. Participants will 
be offered seven one-to-one telephone or internet-based 
audio/video call (based on patient preference) sessions 
(up to 45 min) of CBA or PEP interventions over a period 
of 14 weeks with a trained therapist (figure 2). The first 
session of PEP, however, will be delivered face-to-face. A 
booster session will be conducted at 22 weeks after the 
start of therapy by the relevant healthcare professional.
Training of healthcare professionals as therapists before the study
Separate CBA and PEP training will be provided for the 
NHS staff delivering the interventions. This will comprise 
an intensive 2-day group course delivered by experienced 
designated investigators supplemented with the ther-
apist manuals. The course will use a range of methods 
including skills practice with specific feedback using ficti-
tious but typical fatigued cases.
Supervision and support of therapists during the study
Supervision will be provided by designated investiga-
tors on a fortnightly basis, or as required, to the thera-
pists either face-to-face or by telephone depending on 
feasibility and preference. In addition, support will be 
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available in cases where a therapist requires assistance 
with respect to a particular participant. In addition to the 
option to contact the supervisor directly, we will have a 
notification system incorporated in the database.
Treatment fidelity
Some of the intervention sessions will be recorded and 
used in supervision to provide feedback to therapists and 
to ensure treatment fidelity. We aim to take a 5% sample 
of intervention sessions for those in CBA and PEP from 
participants who agree to be recorded which is based on 
a random sample generated from an algorithm that takes 
into account session number, therapist, site location, 
patient gender. This is equivalent to approximately 89 
recordings per intervention and will be subject to treat-
ment adherence (no sessions completed) and participant 
permission to record sessions.
outcome measures
All outcome and mediator measures will be assessed at 
randomisation (baseline) and then, on average, 10 weeks, 
28 weeks and 56 weeks thereafter (by questionnaire unless 
stated) in all participants (figure 3). The outcome measures 
at each time point and their source (ie, questionnaire, 
medical record, blood sample, diary) are summarised in a 
study matrix (online supplementary table 1).
Figure 3 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) schedule of enrolment, interventions 
and assessments. CBA, cognitive-behavioural approach; PEP, personalised exercise programme.
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Primary outcome measures
The primary outcome, fatigue, is measured with the 
Chalder Fatigue Scale (CF)39 which assesses the physical 
and mental symptoms of fatigue using Likert scoring, and 
the Fatigue Severity Scale (FSS)40 assessing the impact of 
fatigue at 56 weeks post randomisation. If the effect of the 
intervention is positive on the CF, then the FSS outcome 
will be formally analysed. Should the intervention have 
no effect on the CF, then an explorative analysis of the 
FSS data will be performed.
Secondary outcome measures
Secondary outcomes are:
Fatigue: Bristol Rheumatoid Arthritis Fatigue MultiDi-
mensional Questionnaire41 assessing the physical, living, 
cognition and emotional aspects of fatigue.
Quality of life and Health Utility Index: Short 
Form-12 (SF-12)42 assessing functional health and well-
being from the participant’s perspective.
Pain: Pain numerical rating scale43 assessing pain 
intensity.
Anxiety and depression: HADS.37
Sleep: Sleep problem scale.44
Impact on work: Work Productivity and Activity Impair-
ment Questionnaire: Specific Health Problem.45
Impact on activities: Short form of Valued Life Activities 
Scale.46
Global outcome: Change of global health.
Mediator/moderator measures
While many secondary outcome measures may also func-
tion as mediators, or their baseline values as moderators, 
more detailed cognitive, behavioural, clinical and phys-
ical data will be collected in order to fully characterise 
these factors.
Cognitions and behaviours: Brief Illness Percep-
tion Questionnaire,47 Behavioural Response to Illness 
Questionnaire.48
Clinical: Presence of fibromyalgia,49 serological status, 
erosive status, disease duration, previous and current 
pharmacological therapies, disease activity: self-reported 
using a Numeric Rating Scale, Disease Activity Score 
28 (DAS28) for RA (mandatory), other disease-spe-
cific activity measures (non-mandatory), inflammation 
(C-reactive protein (CRP)/Erythrocyte sedimentation 
rate (ESR), presence of other comorbidities (Charlson 
Comorbidity Index).50
Physical: Physical activity and sedentary behaviour 
profiles will be measured by an activity monitor (activPAL, 
Paltechnologies, Glasgow). The activPAL will be fitted to 
the participant at each assessment visit and participants 
will be instructed to remove the device and post it back to 
the research team after 7 days in the stamped addressed 
envelope provided to them.
Quantifying aerobic fitness: A step test, which involves 
participants wearing a heart rate monitor and stepping 
onto a 10-inch high box for 3 min at different stepping 
rates will assess aerobic fitness. Participants stop the test 
if their heart reaches 65% of predicted maximal heart 
rate (220-age or 190-age if the participant is prescribed 
beta-blocker) at the end of any stage. One minute of rest 
is given between stages and maximal oxygen uptake is 
estimated from heart rate recordings according to estab-
lished equations.51 In addition, values of Borg Rating of 
Perceived Exertion are collected.
Neuroimaging data: Participants will have an option 
to undertake a multimodal MRI brain scan (see online 
supplementary file 2).
Furthermore, participants will be given the option to 
provide additional blood samples which will be stored in 
a designated freezer at the University of Aberdeen. These 
will be a maximum of three tubes per visit of 1x PAXgene 
DNA (visit 1 only), 1x PAXgene RNA (visit 1, 2, 3), 1x 
serum (visit 1, 2, 3). Additional consent for their use in 
future unspecified studies will be obtained.
Quantitative process evaluation
Participant preference: Participants will be given a short 
synopsis of all three treatments, usual care, CBA and PEP 
interventions as treatment for IRD-related fatigue at base-
line. They will then be asked about which treatment they 
would choose if they had a choice, as well as about their 
strength of preference.
Participant adherence: Adherence to the interventions 
will be monitored via attendance records kept by the 
therapists. In addition, participants receiving the CBA or 
PEP interventions will be contacted by a member of Trial 
Office in Aberdeen at time of session 4 (approximately 
week 8) and session 8 (approximately week 26) for a tele-
phone interview. They will be asked to indicate on a scale 
from 0 (not at all) to 10 (completely), if they think that 
this treatment is the right approach and their willingness 
to engage and adhere to the intervention. At the same 
time, the therapists will be asked during supervision to 
what extent they think that the participant has engaged 
with treatment and adhered to the agreed actions and 
plans.
Intervention acceptance: Acceptance by participants 
will be evaluated in all three treatment arms using the 
Client Satisfaction Questionnaire52 at 28 weeks.
Qualitative evaluation
A subgroup of participants will be invited to take part 
in a nested qualitative evaluation study. We will conduct 
qualitative evaluations of both participants who received 
CBA or PEP after they completed the 56-week follow-up 
and all therapists who will deliver the interventions. To 
ensure integrity, participants and therapists will be invited 
to take part once they have left or completed the study. 
Data will be collected through semistructured interviews 
conducted by telephone or by internet-based audio/
video calls. In addition to the practical considerations of 
offering options, this approach acknowledges that both 
participants and therapists will have been involved in a 
remotely delivered intervention. All interviews will be 
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audio recorded, anonymised during transcription and 
checked for accuracy.
Participant experiences of the interventions will be anal-
ysed using a framework analysis53 to assess the content, 
mode of delivery, acceptability, barriers and facilitators, 
helpfulness and subsequent impact of the interventions 
on their daily lives. We will use a maximum variation 
sampling strategy54 to include participants with a range 
of IRDs, gender, age, disease duration and primary 
outcomes in the randomised controlled trial. To achieve 
this, a minimum of 40 interviews is required. All selected 
participants will receive additional information after they 
have completed the last assessment visit (week 56) and 
provide separate written informed consent for the quali-
tative component.
All therapists will be invited to take part in a tele-
phone interview to explore experiences of intervention 
training and delivery, including challenges and benefits 
of learning and using new skills, and barriers and facili-
tators to supporting patients remotely using a structured 
manual. This evaluation will be analysed using inductive 
thematic analysis.55 All therapists will receive additional 
information after they have either left the study or after 
the intervention phase and provide separate written 
informed consent for the qualitative component.
Patient safety
There are unlikely to be major safety issues with our 
proposed non-pharmacological interventions. However, 
if the therapists delivering CBA and PEP or any study 
personnel have any safety concerns, we will follow a 
specific standard operating procedure for adverse events 
in non-Clinical Trial of an Investigational Medicinal 
Product (non-CTIMP) studies.
laboratory and sample analysis
This multicentre study involves a number of standard 
blood investigations, that is, thyroid-stimulating hormone 
(TSH), haemoglobin, serum creatinine, CRP and ESR, 
which are routinely processed by local NHS laborato-
ries. Blood samples for CRP and ESR analysis and sample 
storage for future ethically approved research will be 
taken at each assessment as specified in the study matrix 
by trained personnel only following established proce-
dures. Blood samples for TSH, haemoglobin and serum 
creatinine analysis will only be taken at baseline if they are 
required to confirm eligibility. Sample coding, prepara-
tion, storage, analysis and transfer of results and optional 
blood samples for long-term storage at the trial centre will 
be performed according to the analytical protocol based 
on national laboratory guidelines. The exact logistic and 
procedure will be agreed with each site before the start of 
the study and every effort will be made to standardise the 
workflow across sites to reduce bias. Additional optional 
blood samples will be stored for future ethically approved 
research. All study blood results (abnormal or other-
wise) will also be directed towards the local principal 
investigator (PI) who can determine locally how these will 
be handled.
Withdrawal procedures
Participants will have the option to withdraw at any time 
during the study period of 13 months. The participant 
needs to request this formally and a withdrawal document 
will be completed and signed by the designated research 
staff at the local sites. They have the option to either 
withdraw from the study completely or from parts of it 
(prestudy invite, treatment or follow-up). If participants 
withdraw from the study completely or from follow-up 
assessments, they will not receive further invitations but 
we will use the data collected prior to the withdrawal 
(depending on permission). Those withdrawing from 
the treatment only will continue to be sent invitations to 
attend and complete follow-up assessment visits, unless 
they request to withdraw completely later on. Failure of 
any participant to complete a follow-up at any particular 
time point will not be counted as a withdrawal unless the 
participant formally requests to withdraw. In addition, a 
participant can also be withdrawn by others, for example, 
the local PI or primary consultant, should the need 
arise at any stage throughout the study period. This also 
includes loss of capacity for ongoing consent.
statistical issues
Sample size
Our planned primary intention-to-treat analyses will 
compare PEP+usual care versus usual care alone, and 
CBA+usual care versus usual care alone separately. We 
base our calculations on a standardised effect size of 0.50 
(considered credible in other pragmatic effectiveness 
studies). This would equate to being powered to detect 
a minimal important clinical difference of 2 units in the 
CF Scale, assuming a common SD across the randomised 
groups of 4 units. Assuming an overall significance level 
of 5% (by calculating the two prespecified randomised 
groups comparisons, PEP+usual care vs usual care alone 
and CBA+usual care vs usual care alone, at 2.5%, to main-
tain an overall level of not more than 5%) and a power of 
90%, we require 100 evaluable participants in each of the 
three groups.
The data of participants are evaluable when outcomes 
at the 56 weeks follow-up are available. Based on our own 
previous studies, we estimate a drop-out rate of 20%, 
and therefore, we anticipate recruiting 375 participants 
randomly allocating 125 into each treatment group.
Statistical analysis
All statistical analyses will be governed by a comprehensive 
statistical analysis plan, which will be authored by the trial 
statistician and approved by the trial steering committee 
(TSC) and the data monitoring committee before the 
main study outcome data are examined. All analyses 
will be carried out using standard statistical software. In 
accordance with Consolidated Standards of Reporting 
Trials guidelines,56 we will report all participant flow 
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through the study. Descriptive statistics of recruitment, 
drop-out and completeness of interventions will be 
provided.
Effectiveness analysis
The main effectiveness analysis will be via intention-to-
treat including all participants, with no planned interim 
analysis for early termination for either overwhelming 
evidence of effectiveness or abandoning for futility. Base-
line characteristics will be presented by randomised group 
without formal statistical tests. We will test the primary 
hypothesis for between-group change in the primary 
outcome for each of the two prespecified comparisons 
(CBA+usual care vs usual care alone and PEP+usual care vs 
usual care alone) using repeated measures mixed model, 
with subject as a random effect, and a suitably specified 
covariance structure (eg, autoregressive[1] (AR[1]), 
therapist as a random effect (to adjust for any clustering 
by therapist), with baseline outcome measure, and any 
other strongly predictive baseline measures, including 
the minimisation factors of presence/absence of depres-
sion and centre. Treatment and its interaction with time 
will be fitted as fixed effects, and we will apply standard 
regression diagnostics. The analysis will use statistical 
techniques for handling missing outcome data using 
multiple imputation under a missing at random (MAR) 
assumption. The secondary outcomes will be analysed 
using an analogous method. The main estimate of treat-
ment effect will focus on the 56 weeks after baseline.
Mediation analysis
We will use modern causal inference methods to inves-
tigate the set of mediator measures. If the effectiveness 
analysis shows significance between-group differences 
in the mediators, then we will use parametric regression 
models to test for the effect of mediator on an outcome 
and the residual direct effect of treatment on outcome. 
Since all the measures are continuous, the indirect 
effects will be calculated by multiplying relevant path-
ways and bootstrapping will be used to produce valid SEs 
for the indirect effects. All analyses will adjust for base-
line measures of the mediators, outcome and putative 
measured confounders. Mediation analyses are poten-
tially biased by measurement error in mediators and 
hidden confounding between mediators and outcomes; 
we will build on our previous methodological and applied 
work in this context to include repeated measurement of 
mediators and outcomes to account for classical measure-
ment error and baseline confounding.
Moderation analysis
We will examine differential treatment effects using 
the set of moderator measures by extending the inten-
tion-to-treat analysis models to include an interaction 
term between intervention and each of the modera-
tors separately. We will use bias correction/cross-valida-
tion methods to identify robust evidence for individual 
moderation and for a moderation index, both on the 
overall effect and also along the steps of the mediation 
pathway.
Every effort will be made to ensure data collection is 
complete. However, we will use statistical techniques 
for handling missing outcome data. Multiple imputa-
tion under an MAR assumption will be used in the first 
instance, with additional sensitivity analysis if the MAR 
assumption is not satisfied.
health economics evaluation
An economic evaluation will be conducted from both 
a healthcare system and societal perspective. Partici-
pants will be asked to record, in a diary, all types and 
duration of hospital admissions, a frequency of visits to 
the hospital for outpatient attendances and other visits 
to or from relevant health professionals (eg, general 
practitioners, nurse practitioners, physiotherapists) 
and specify whether the main reason for the visit was 
fatigue. Each participant will be asked to keep the 
diaries between the baseline and third assessment visit 
(approximately 28 weeks). Furthermore, they will be 
asked to keep diaries for 2 weeks after the third assess-
ment visit and 2 weeks before they return for the last 
assessment visit. National sources of unit cost data will 
be applied to value resource use (Healthcare Resource 
Group (HRG) Reference Costs, Unit Costs of Health 
and Social Care). The costs associated with a delivery 
of the interventions will be estimated using records 
kept by therapists of the number and duration of calls 
per participant.
Participants will be asked to report any contacts with 
private practitioners, and the costs of over-the-counter 
medication/complementary therapies purchased. This also 
includes additional expenses related to their condition or 
fatigue as well as if there was an impact on paid and unpaid 
work.
Health-related quality of life data will be collected using 
the SF-12 and these data will be converted to the quality 
of life weights using published tariffs. These data will 
then be used to calculate quality-adjusted life years. As 
the intervention may affect general well-being as well as 
reduce fatigue, we will also collect values for changes in 
well-being data using the Investigating Choice Experie-
ments for the preference of older people CAPability 
measure for Adults (ICECAP) instrument57 and changes 
in life satisfaction.58
study management and conduct
The study will be coordinated by a trial management 
group, consisting of the grant holder chief investi-
gator (CI), additional members of the research group, a 
study coordinator and a representative from Centre for 
Healthcare and Randomised Trials (CHaRT).
A TSC has been established. The TSC comprises an 
independent chair who has expertise in trials and other 
members, both independent and study investigators, with 
a background relevant to IRD or type of interventions 
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including a lay representative, who has lived experience 
of IRD-related fatigue, and a clinician working with 
people with IRD.
An independent data monitoring committee has been 
established to oversee study progress. The data moni-
toring committee comprises a chair who has expertise 
in trials, a biostatistician and two other independent 
members with a rheumatology background.
End of study
The end of study is defined as last data collection of either 
the qualitative evaluation study phase or during the last 
follow-up visit at 56 weeks from the last participant after 
CBA/PEP intervention or usual care start date —which-
ever comes last.
data management, protection, storage and archiving of study 
documents
All investigators and study staff involved with this study 
will comply with the requirements of the Data Protection 
Act 2018 with regard to the collection, storage, processing 
and disclosure of personal information and will uphold 
the Act’s core principles. The investigators and study staff 
will also adhere, if appropriate, to the current version of 
the NHS Scotland Code of Practice on Protecting Patient 
Confidentiality. Access to collated participant data will be 
restricted to the CI and appropriate study staff as needed. 
All laboratory specimens, evaluation forms, reports and 
other records will be identified using unique participant 
ID numbers to maintain participant confidentiality. All 
records will be kept in a secure storage area with limited 
access to study staff only. Personal data, including postal 
address, phone numbers (ie, landline and mobile), email 
addresses and anonymised data files for study outcomes 
are stored in locked filing cabinets (hard copy) and in a 
bespoke database provided and maintained by CHaRT as 
well as secured shared drives with access via password-con-
trolled computers (university and NHS networks) by 
study staff only (electronic data).
All study documentation will be kept for a minimum of 
5 years from the protocol defined end of study point in 
the University of Aberdeen archive. When the minimum 
retention period has elapsed, study documentation will 
not be destroyed without permission from the sponsor.
Patient and public involvement
Patients and their carers were involved in the development 
of the research question and the prioritisation of fatigue as a 
subject for research. We have benefited from collaborations 
with representatives of the National Rheumatoid Arthritis 
Society, the National Ankylosing Spondylitis Society and 
Lupus UK who have significantly influenced the trial design. 
In addition, we have worked with patient advisory groups 
which provided valuable input into the content and layout 
of the information material and other documents that will 
be given to the participants to assess the burden of the inter-
vention and data collection visits. Although patients were 
not actively involved in the recruitment, they are involved in 
the conduct of the study as lay representatives on the TSC. 
After completion of the study, the main results and conclu-
sions of the study will be disseminated to participants in lay 
language in form of a newsletter.
dIsCussIon
The LIFT trial is a pragmatic multicentre, three-arm 
randomised controlled trial. It has been designed to test 
the effectiveness and cost-effectiveness of remotely deliv-
ering two non-pharmacological interventions, CBA and 
PEP, over a period of 22 weeks so as to answer whether 
treatment can move beyond face-to-face disease-spe-
cific interventions for IRD-related fatigue. In order to 
achieve the study aims, the CBA and PEP interventions 
were informed by previous evidence-based cognitive 
behavioural and exercise interventions31 32 for fatigue 
to ensure suitability across IRD conditions, as well as 
to ensure that both interventions could be delivered 
via telephone or internet-based audio/video calls by a 
range of rheumatology healthcare professionals trained 
as therapists. To reduce selection bias, all patients with a 
relevant diagnosis, managed at each recruiting site who 
report fatigue as a persistent problem will be considered, 
either through database screening or manual screening 
by research nurses, and invited to take part in the trial. 
Participants will be asked to provide information about 
fatigue, our primary outcome, at baseline and weeks 10, 
28 and 56 using the CF and FSS to measure severity and 
impact at critical times throughout the trial. In addition, 
detailed information on cognitions and behaviours (eg, 
illness perception), clinical features (eg, disease activity, 
presence of fibromyalgia), as well as physical activity and 
fitness levels will allow for the identification of potential 
moderators and mediators of the treatment effect in this 
trial. Although complete blinding is not possible due to 
the provision of an active behavioural change interven-
tion, we aim to reduce detection bias by asking participants 
to refrain from revealing their treatment allocation to the 
research nurses undertaking their outcome assessments.
Fatigue remains a significant patient-identified 
priority, as well as a significant challenge to manage 
clinically. To provide the necessary evidence to bring 
about change in health services consistently offered for 
IRD-related fatigue across the spectrum of IRD condi-
tions, both a quantitative and qualitative evaluation will 
also be undertaken within the trial. Trial findings will be 
used to inform future triage of patients into the most 
suitable intervention, as well as provide evidence of 
which mediating factors play a role in treatment effect 
among patients with IRD-related fatigue.
Ethics and dissemination
The study will be conducted in accordance with the prin-
ciples of Good Clinical Practice.
Extension of recruitment for 6 months was approved 
and implemented as minor amendment 09 on 
17 September 2018 (protocol V.7, current). Management 
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approval from all NHS health boards was obtained as 
required by the ethics committee before the start of the 
study.
Consent will be sought for the recording of interven-
tions sessions for quality assurance and treatment fidelity. 
Written consent will be obtained to record interviews and 
to include anonymised statements in the publication of 
the qualitative evaluation outcomes.
Ownership of the data arising from this study resides 
with the University of Aberdeen.
A clinical study report will be prepared in accordance 
with International Council for Harmonisation (ICH) 
authorship guidelines which will be used for dissemina-
tion of findings via the publication and presentation at 
scientific meetings. Investigators have the right to publish 
orally or in writing the results of the study.
There are no plans to place study outcome data in a 
repository at the current time.
trial status
The LIFT study began recruitment in August 2017 and will 
be ongoing until March 2019 (anticipated). It is expected 
that data collection will be completed by April 2020.
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